Abstract：
BACKGROUND: Evidence suggests that children who had received an initial priming dose of whole-cell pertussis (wP) vaccine, rather than acellular pertussis (aP) vaccine, had a lower risk of developing IgE-mediated food allergy, the most common cause of anaphylaxis-related hospital presentations of childhood.
OBJECTIVE: To assess the association between wP versus aP vaccination in infancy and subsequent hospital presentations for anaphylaxis.
METHODS: This study was preregistered under PMID 34874968. Perinatal records for a cohort of New South Wales-born children (1997-1999) receiving their first dose of pertussis-containing vaccine before age 4 months were probabilistically linked to hospital and immunization records. We used adjusted Cox models to estimate hazard ratios (aHRs) and 95% CIs for anaphylaxis-coded hospitalizations.
RESULTS: There were 218,093 New South Wales-born children who received a first dose of wP or aP before age 4 months. Among these children, 86 experienced at least one hospitalization for food-induced anaphylaxis at age 5-15 years (range of events per patient, one to three). The person-time of follow-up was 1,476,969 years, and 665,519 years for children vaccinated with wP as a first dose (wP-1 children) and aP as a first dose (aP-1 children), respectively. The incidence rates for first hospitalization for food anaphylaxis were 3.5 (95% CI, 2.6-4.6) and 5.1 (95% CI, 3.5-7.1) per 100,000 child-years among wP-1 children and aP-1 children, respectively (aHR for wP vs aP = 0.47; 95% CI, 0.26-0.83). For first admission for venom anaphylaxis, the incidence rate was 4.9 (95% CI, 3.9-6.2) per 100,000 child-years among wP-1 children and 5.1 (95% CI, 3.5-7.1) per 100,000 child-years among aP-1 children (aHR for wP vs aP = 0.92; 95% CI, 0.53-1.60), and for all-cause anaphylaxis, the incidence rate was 10.6 (95% CI, 9.0-12.4) per 100,000 child-years among wP-1 children and 12.8 (95% CI, 10.2-15.8) per 100,000 child-years among aP-1 children (aHR for wP vs aP = 0.92; 95% CI, 0.53-1.60).
CONCLUSIONS: Vaccination with wP in infancy was associated with a lower risk of hospitalizations for food-induced anaphylaxis (and therefore severe IgE-mediated food allergy) occurring in childhood.
OBJECTIVE: To assess the association between wP versus aP vaccination in infancy and subsequent hospital presentations for anaphylaxis.
METHODS: This study was preregistered under PMID 34874968. Perinatal records for a cohort of New South Wales-born children (1997-1999) receiving their first dose of pertussis-containing vaccine before age 4 months were probabilistically linked to hospital and immunization records. We used adjusted Cox models to estimate hazard ratios (aHRs) and 95% CIs for anaphylaxis-coded hospitalizations.
RESULTS: There were 218,093 New South Wales-born children who received a first dose of wP or aP before age 4 months. Among these children, 86 experienced at least one hospitalization for food-induced anaphylaxis at age 5-15 years (range of events per patient, one to three). The person-time of follow-up was 1,476,969 years, and 665,519 years for children vaccinated with wP as a first dose (wP-1 children) and aP as a first dose (aP-1 children), respectively. The incidence rates for first hospitalization for food anaphylaxis were 3.5 (95% CI, 2.6-4.6) and 5.1 (95% CI, 3.5-7.1) per 100,000 child-years among wP-1 children and aP-1 children, respectively (aHR for wP vs aP = 0.47; 95% CI, 0.26-0.83). For first admission for venom anaphylaxis, the incidence rate was 4.9 (95% CI, 3.9-6.2) per 100,000 child-years among wP-1 children and 5.1 (95% CI, 3.5-7.1) per 100,000 child-years among aP-1 children (aHR for wP vs aP = 0.92; 95% CI, 0.53-1.60), and for all-cause anaphylaxis, the incidence rate was 10.6 (95% CI, 9.0-12.4) per 100,000 child-years among wP-1 children and 12.8 (95% CI, 10.2-15.8) per 100,000 child-years among aP-1 children (aHR for wP vs aP = 0.92; 95% CI, 0.53-1.60).
CONCLUSIONS: Vaccination with wP in infancy was associated with a lower risk of hospitalizations for food-induced anaphylaxis (and therefore severe IgE-mediated food allergy) occurring in childhood.
摘要：
背景：证据表明，接受过初始启动剂量的全细胞百日咳（wP）疫苗的儿童，而不是无细胞百日咳（aP）疫苗，发生IgE介导的食物过敏的风险较低，儿童过敏反应相关的医院介绍的最常见原因。
目的：评估婴儿期wP与aP疫苗接种与随后住院的过敏反应之间的关系。
方法：本研究在PMID：34874968下预先注册。新南威尔士州（NSW）出生的儿童（1997-1999年）在4个月大之前接受第一剂含百日咳疫苗的围产期记录与医院和免疫记录有概率联系。调整后的Cox模型用于估计过敏反应编码的住院治疗的风险比（aHRs）和95％置信区间（CIs）。
结果：有218,093名新南威尔士州出生的儿童在4个月大之前接受了第一剂wP或aP。在这些孩子中,86例患者在5至15岁期间至少因食物引起的过敏反应住院（每个患者的事件范围：1至3）。首次接种wP（wP-1儿童）和首次接种aP（aP-1儿童）的儿童的随访时间为1,476,969年和665,519年，分别。在wP-1儿童和aP-1儿童中，首次因食物过敏反应住院的发生率分别为每100,000儿童年3.5（95％CI2.6-4.6）和5.1（95％CI3.5-7.1）（wP-1儿童的aHR与aP0.47；95％0.26-0.83）。首次接受毒液过敏反应时，wP-1儿童的发病率为每100,000儿童中的4.9（95％CI3.9-6.2），aP-1儿童中的每100,000儿童中的5.1（95％CI3.5-7.1）（wP的aHR与aP0.92；95％0.53-1.60），wP-1儿童和aP-1儿童中每100,000儿童年全因过敏反应10.6例(95%CI9.0-12.4)和aP-1儿童中每100,000儿童年全因过敏反应12.8例(95%CI10.2-15.8)(wP的aHR与aP0.92;95%CI0.53-1.60)结论:婴儿期接种wP疫苗与食物诱导的儿童过敏性反应(因此发生严重住院风险
目的：评估婴儿期wP与aP疫苗接种与随后住院的过敏反应之间的关系。
方法：本研究在PMID：34874968下预先注册。新南威尔士州（NSW）出生的儿童（1997-1999年）在4个月大之前接受第一剂含百日咳疫苗的围产期记录与医院和免疫记录有概率联系。调整后的Cox模型用于估计过敏反应编码的住院治疗的风险比（aHRs）和95％置信区间（CIs）。
结果：有218,093名新南威尔士州出生的儿童在4个月大之前接受了第一剂wP或aP。在这些孩子中,86例患者在5至15岁期间至少因食物引起的过敏反应住院（每个患者的事件范围：1至3）。首次接种wP（wP-1儿童）和首次接种aP（aP-1儿童）的儿童的随访时间为1,476,969年和665,519年，分别。在wP-1儿童和aP-1儿童中，首次因食物过敏反应住院的发生率分别为每100,000儿童年3.5（95％CI2.6-4.6）和5.1（95％CI3.5-7.1）（wP-1儿童的aHR与aP0.47；95％0.26-0.83）。首次接受毒液过敏反应时，wP-1儿童的发病率为每100,000儿童中的4.9（95％CI3.9-6.2），aP-1儿童中的每100,000儿童中的5.1（95％CI3.5-7.1）（wP的aHR与aP0.92；95％0.53-1.60），wP-1儿童和aP-1儿童中每100,000儿童年全因过敏反应10.6例(95%CI9.0-12.4)和aP-1儿童中每100,000儿童年全因过敏反应12.8例(95%CI10.2-15.8)(wP的aHR与aP0.92;95%CI0.53-1.60)结论:婴儿期接种wP疫苗与食物诱导的儿童过敏性反应(因此发生严重住院风险
